Arms |
Assigned Interventions |
Experimental:Monotherapy Telisotuzumab vedotin (21-day dosing cycles)
Telisotuzumab vedotin will be administered at escalating dose levels in 21-day dosing cycles. Additional subjects will be enrolled in an expansion cohort that will further evaluate Telisotuzumab vedotin.
|
Experimental:Monotherapy Telisotuzumab vedotin(28-day dosing cycles)
Telisotuzumab vedotin will be administered at escalating dose levels in 28-day dosing cycles. Additional subjects will be enrolled in an expansion cohort that will further evaluate Telisotuzumab vedotin.
|
Experimental:Arm A (Telisotuzumab vedotin plus Erlotinib)
Telisotuzumab vedotin to be evaluated with Erlotinib.
|
Drug:Erlotinib It is administered orally everyday. |
Experimental:Arm D (Telisotuzumab vedotin plus Nivolumab)
Telisotuzumab vedotin to be evaluated with Nivolumab.
|
Drug:Telisotuzumab vedotin It is administered by infusion in 28-day dosing cycles. |
Experimental:Arm E (Telisotuzumab vedotin plus Osimertinib)
Telisotuzumab vedotin to be evaluated with Osimertinib.
|
Drug:Osimertinib It is administered orally everyday. |